← Leaderboards
Stefan Worgall
Weill Medical Coll Of Cornell Univ
$14,468,848
Attributed
$15,404,481
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,404,481 · 11
By mechanism
R01$11,415,641 · 6
U01$2,105,107 · 1
R21$1,883,733 · 4
Top collaborators
- Stephen Michael Kaminsky3 shared
- Ronald G Crystal2 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionResponseCellsVaccinesAntibodiesGeneticGenesImmunityImmunizationImmune ResponseAdenovirusesVectorBaseCapsidBinding (Molecular Function)AdjuvantImmuneLungPathogenAdultRespiratory SystemAntigensAdenovirus VectorIn Vivo
Grant awards (35)
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma$844,058
R01 · FY2025 · AI · contact PI
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma$796,394
R01 · FY2025 · AI · contact PI
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma$837,786
R01 · FY2024 · AI · contact PI
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma$799,479
R01 · FY2024 · AI · contact PI
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma$884,376
R01 · FY2023 · AI · contact PI
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma$812,349
R01 · FY2023 · AI · contact PI
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis$211,875
R21 · FY2023 · AI · contact PI
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis$269,375
R21 · FY2022 · AI · contact PI
Rhinovirus respiratory infection and sphingolipid metabolism$252,000
R21 · FY2019 · AI · contact PI
Rhinovirus respiratory infection and sphingolipid metabolism$227,292
R21 · FY2018 · AI · contact PI
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors$423,750
R01 · FY2016 · AI · contact PI
Mucosal Delivery of RSV Neutralizing Antibody and Antigens$254,250
R21 · FY2016 · AI · contact PI
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors$423,750
R01 · FY2015 · AI · contact PI
Mucosal Delivery of RSV Neutralizing Antibody and Antigens$211,875
R21 · FY2015 · AI · contact PI
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors$423,750
R01 · FY2014 · AI · contact PI
Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors$398,129
R01 · FY2013 · AI · contact PI
Adenovirus-based Nanoparticle Vaccines$350,548
R01 · FY2013 · DA
Adenovirus-based Nanoparticle Vaccines$365,155
R01 · FY2012 · DA
Immunity Induced by Modified Adenovirus Fiber$403,822
R01 · FY2011 · AI · contact PI
Adenovirus-based Nanoparticle Vaccines$374,185
R01 · FY2011 · DA
Immunization Against Pseudomonas aeruginosa by Modified Ad Vectors$426,483
U01 · FY2010 · AI · contact PI
Vaccination Against RSV with Capsid-modified Ad Vectors$422,500
R01 · FY2010 · AI · contact PI
Immunity Induced by Modified Adenovirus Fiber$407,901
R01 · FY2010 · AI · contact PI
Adenovirus-based Nanoparticle Vaccines$401,128
R01 · FY2010 · DA
Immunization Against Pseudomonas aeruginosa by Modified Ad Vectors$422,317
U01 · FY2009 · AI · contact PI
Vaccination Against RSV with Capsid-modified Ad Vectors$422,291
R01 · FY2009 · AI · contact PI
Immunity Induced by Modified Adenovirus Fiber$412,020
R01 · FY2009 · AI · contact PI
Adenovirus-based Nanoparticle Vaccines$380,250
R01 · FY2009 · DA
Immunization Against Pseudomonas aeruginosa by Modified Ad Vectors$419,669
U01 · FY2008 · AI · contact PI
Immunity Induced by Modified Adenovirus Fiber$412,020
R01 · FY2008 · AI · contact PI
Immunity Induced by Modified Adenovirus Fiber$420,000
R01 · FY2007 · AI · contact PI
Immunization Against Pseudomonas aeruginosa by Modified Ad Vectors$416,638
U01 · FY2007 · AI · contact PI
Immunization Against Pseudomonas aeruginosa by Modified Ad Vectors$420,000
U01 · FY2006 · AI · contact PI
Interaction of P. aeruginosa with Alveolar Macrophages$205,066
R21 · FY2006 · HL · contact PI
Interaction of P. aeruginosa with Alveolar Macrophages$252,000
R21 · FY2005 · HL